Rani Therapeutics Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RANI research report →
Companywww.ranitherapeutics.com
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing.
- CEO
- Talat Imran
- IPO
- 2021
- Employees
- 105
- HQ
- San Jose, CA, US
Price Chart
Valuation
- Market Cap
- $71.20M
- P/E
- -6.66
- P/S
- 22.47
- P/B
- 6.91
- EV/EBITDA
- -1.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.92%
- Op Margin
- -1092.96%
- Net Margin
- -929.06%
- ROE
- -245.45%
- ROIC
- -87.72%
Growth & Income
- Revenue
- $1.63M · 58.85%
- Net Income
- $-29,673,000 · 1.15%
- EPS
- $-0.45 · 57.14%
- Op Income
- $-38,310,000
- FCF YoY
- 47.43%
Performance & Tape
- 52W High
- $3.87
- 52W Low
- $0.39
- 50D MA
- $0.99
- 200D MA
- $1.13
- Beta
- 0.76
- Avg Volume
- 1.26M
Get TickerSpark's AI analysis on RANI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Javadi Alireza | other | 0 |
| Mar 18, 26 | Javadi Alireza | other | 9,166 |
| Mar 18, 26 | Javadi Alireza | other | 3,416 |
| Mar 18, 26 | Javadi Alireza | other | 17,084 |
| Mar 18, 26 | Javadi Alireza | other | 40,750 |
| Mar 18, 26 | Javadi Alireza | other | 159,000 |
| Oct 23, 25 | Bailey Vasudev Jaiprakash | other | 100,000 |
| Oct 23, 25 | Bailey Vasudev Jaiprakash | other | 0 |
| Oct 23, 25 | Bassan Abraham | other | 100,000 |
| Oct 23, 25 | Bassan Abraham | other | 0 |
Our RANI Coverage
We haven't published any research on RANI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RANI Report →